Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their target price on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.

Evogene Stock Up 2.5 %

Shares of Evogene stock opened at $2.88 on Friday. The stock’s 50-day simple moving average is $4.36 and its 200-day simple moving average is $6.28. The company has a market capitalization of $11.87 million, a price-to-earnings ratio of -6.26 and a beta of 1.40. Evogene has a 52 week low of $2.80 and a 52 week high of $10.40.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%. The company had revenue of $0.91 million during the quarter.

Hedge Funds Weigh In On Evogene

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets increased its stake in Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the period. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 as of its most recent SEC filing. 10.40% of the stock is currently owned by institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.